Healthcare AI company Huma Therapeutics has completed its Series D funding round, amassing over $80m to facilitate the launch of its Huma Cloud Platform.
Huma Cloud Platform integrates GenAI to streamline digital-first care and research.
The Series D financing, combined with investments since the Series C round, brings Huma's total capital raised to over $300m.
This round featured contributions from both new and existing investors, including Hat Technology Fund 4 by HAT SGR, AstraZeneca, HV Fund by Hitachi Ventures, Leaps by Bayer, among others.
HSBC Bank provided advisory services to Huma during the fundraising process.
The Huma Cloud platform is designed to offer a no-code configuration of regulated disease management tools across various therapeutic regions.
It includes a comprehensive library of pre-built modules, device connectivity, a cloud-agnostic framework, APIs, and the capacity to host and deploy diagnostic and predictive AI algorithms.
Additionally, it features a marketplace to further support the advancement of digital-first care and research.
Huma Cloud Platform is an ecosystem aimed at supporting the company's digital health initiatives and enabling others to launch and scale their projects.
With this platform, Huma intends to drastically reduce the development and launch time of digital health projects from years to mere days.
The platform has been constructed to complement Huma's existing regulated products, significantly diminishing the costs, time, and risks typically associated with digital health project development.
Huma's technology has already been utilised in over 3,000 hospitals and clinics worldwide, demonstrating its substantial impact on the healthcare sector.
Huma founder and CEO Dan Vahdat said: “We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy.
“We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive.”
